Krsnaa Diagnostics has issued 16.21 lakh convertible warrants to its promoter group at Rs 566 per share. The company has successfully raised Rs 22.94 crore as an initial 25% subscription payment. This move strengthens promoter holding and provides the company with future capital infusion as warrants convert over the next 18 months.
Krsnaa Diagnostics Allots 16.21 Lakh Warrants to Promoters
16,21,000 warrants issued at Rs 566 per unit; Rs 22.94 crore initial capital received.
Reader Takeaway: Promoter commitment increases via equity infusion, though future conversion will expand total equity base and dilute shares.
What just happened
Krsnaa Diagnostics has completed the allotment of 16,21,000 fully convertible warrants to promoter and promoter group entities. The allotment was finalized by the company's Operation Committee on October 13, 2026. This follows the board's initial approval in August and shareholder authorization granted in September. The company has collected 25% of the total issue price, totaling approximately Rs 22.94 crore.
Why this matters
This preferential issue acts as a strategic capital-raising exercise. By subscribing to these warrants, the promoter group is signaling confidence in the long-term prospects of the company. These warrants can be converted into fully paid-up equity shares (face value Rs 5) at Rs 566 each. The conversion process is flexible and can be exercised in tranches over the next 18 months.
Shareholding Impact
Upon full conversion, the promoter group's shareholding in Krsnaa Diagnostics is projected to rise from 27.11% to 29.70%. This consolidation of ownership reflects a deeper financial alignment between the promoters and the company’s future growth targets.
Risks to watch
Investors should monitor the 18-month conversion window. While this provides a capital infusion pathway, the eventual conversion of these warrants will expand the total equity base, which may lead to share dilution for existing shareholders. The exercise of these warrants remains subject to market conditions and the company's operational requirements.
What to track next
Watch for further announcements regarding the exercise of conversion tranches. Additionally, keep an eye on how the company deploys the capital raised, as this will influence its balance sheet strength and growth trajectory in the diagnostic services market.